At Chimerix, we’re dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients.
Incorporated in 2000, Chimerix is a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.
We believe that antivirals that could reduce the frequency of these and other DNA viruses and potentially avoid increasing the risk of other opportunistic infections could provide measureable clinical and pharmacoeconomic benefits for patients and the healthcare system. Through work to date, we see significant opportunities to apply the lipid conjugate technology to other disease categories that are also characterized by a need for effective treatments.
We make commitments and live up to them. By empowering individuals to take ownership and harnessing the agility of our organization, we are able to deliver on our promises—exceeding expectations of quality, value and timeliness.
We are entrepreneurs who leverage both scientific ingenuity and business expertise to develop creative solutions that transform our industry.
We hold ourselves to the highest standards of ethical behavior, demonstrating honesty, fairness, and professionalism in every action that we take.
We embrace unique talents, honor diverse life and work styles, value the contributions of others, and treat everyone with dignity.
We promote an environment of trust and conduct ourselves with openness and candor in order to foster collaboration throughout our organization.